| First Author | Espinosa-Carrasco G | Year | 2024 |
| Journal | Cancer Cell | Volume | 42 |
| Issue | 7 | Pages | 1202-1216.e8 |
| PubMed ID | 38906155 | Mgi Jnum | J:350998 |
| Mgi Id | MGI:7665125 | Doi | 10.1016/j.ccell.2024.05.025 |
| Citation | Espinosa-Carrasco G, et al. (2024) Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42(7):1202-1216.e8 |
| abstractText | Tumor-specific CD8(+) T cells are frequently dysfunctional and unable to halt tumor growth. We investigated whether tumor-specific CD4(+) T cells can be enlisted to overcome CD8(+) T cell dysfunction within tumors. We find that the spatial positioning and interactions of CD8(+) and CD4(+) T cells, but not their numbers, dictate anti-tumor responses in the context of adoptive T cell therapy as well as immune checkpoint blockade (ICB): CD4(+) T cells must engage with CD8(+) T cells on the same dendritic cell during the effector phase, forming a three-cell-type cluster (triad) to license CD8(+) T cell cytotoxicity and cancer cell elimination. When intratumoral triad formation is disrupted, tumors progress despite equal numbers of tumor-specific CD8(+) and CD4(+) T cells. In patients with pleural mesothelioma treated with ICB, triads are associated with clinical responses. Thus, CD4(+) T cells and triads are required for CD8(+) T cell cytotoxicity during the effector phase and tumor elimination. |
